Navigation Links
GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling
Date:3/26/2009

Leading Sucralose manufacturer Guangdong Food Industry Institute/L&P Food Ingredient Co. Ltd. (GDFII/L&P) today announced that the U.S. International Trade Commission (ITC) in Washington D.C. has extended the target date of its final decision in the sucralose case, from March 25 to April 3. This Section 337 patent dispute (docket# 337-TA-604) was filed against the company by its main competitor, Tate & Lyle Corporation (T&L)

Exeter, California (PRWEB) March 26, 2009 -- Leading Sucralose manufacturer Guangdong Food Industry Institute/L&P Food Ingredient Co. Ltd. (GDFII/L&P) today announced that the U.S. International Trade Commission (ITC) in Washington D.C. has extended the target date of its final decision in the sucralose case, from March 25 to April 3. This Section 337 patent dispute (docket# 337-TA-604) was filed against the company by its main competitor, Tate & Lyle Corporation (T&L).

"GDFII/L&P was the first company to manufacture sucralose outside of the U.S.A and continues to be committed to meeting its customer needs of high capacity and superior grade sucralose in the growing sucralose market in the United States and elsewhere, and remains confident of a positive outcome once the ITC issues its final determination," notes Mr. Sanyong Wang, a corporate officer of GDFII/L&P.

Mr. Bassam Faress, spokesperson of GDFII/L&P and Director of Sales/Marketing at Ingredients Specialties, Inc., a global alliance partner of GDFII/L&P, adds "we continue to look forward to this anticipated positive final ruling as we move ahead with our strategic marketing and expansion plans for Sucralose."

The U.S. ITC governs investigations into allegations of unfair trade practices and had in its September 2008 initial determination issued by Administrative Law Judge Charles E. Bullock of the ITC, noted that GDFI
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2

Related biology technology :

1. Mylan Confirms Four First-to-File Challenges
2. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
3. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
4. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
5. Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg
6. Brazilian Sugarcane Industry: OECD Report Confirms Overall Benefits of Brazilian Sugarcane Ethanol
7. ATS Medical Confirms Excellent Durability of the ATS Open Pivot Mechanical Heart Valve
8. Superior Patient Clinical Outcomes Confirms DaVitas Leadership Position on Quality Dialysis Care
9. ProMetic Further Confirms Performance of Prion Capture Resin at the Recovery of Biological Products Conference
10. Barr Confirms Patent Challenge of Prevacid(R) SoluTab(TM) Delayed-Release Orally Disintegrating Tablets, 15mg and 30mg
11. Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling
(Date:11/22/2014)... The “Chiral Chromatography Columns Market ... (Metal, Glass, Plastic), by Application [GC, LC (HPLC, ... to 2018” analyses and studies the major market ... Europe, Asia, and Rest of the World. , ... spread through 135 pages and in-depth TOC on ...
(Date:11/22/2014)... Quebec , November 21, 2014 ... wechselt als Chief Commercial Officer zu KLOX ... SVP der Unternehmensentwicklung und Chief Financial Officer bestellt    ... Europa mit der Vermarktung seines jüngst zugelassenen Behandlungssystems zur ... Inc. ("KLOX" bzw. das "Unternehmen") ist sehr erfreut, die ...
(Date:11/21/2014)... 2014 The science of light and ... with more than 200 primary students in a traveling ... University of Otago Physics Department and funded by an ... members of the university’s OSA/SPIE Student Chapter visited six ... giving children from small, rural schools hands-on lessons in ...
(Date:11/21/2014)... 2014 The California Healthcare ... organization representing leading California academic institutions, biotechnology, medical ... US today released a report revealing that ... growth. The trend shows a 4 percent increase ... Biomedical Industry Report indicates that, while biopharmaceutical ...
Breaking Biology Technology:Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4
... November 2007, BARCELONA, Spain, October 9 ... 332 patients,with Overactive Bladder (OAB) and has been ... Spain, The Netherlands, Czech Republic, Hungary,Poland, Russia, South ... report the results of this trial during November. ...
... PARI Respiratory Equipment,s,breath-enhanced nebulizer, the PARI LC ... new COPD medication, Perforomist Inhalation Solution,that launched ... of Mylan Inc.,(NYSE: MYL ). ... for,long-term, twice-daily maintenance treatment of bronchoconstriction for,emphysema ...
... Solution, to Orthopedic Imaging, PARIS and ATLANTA, Oct. ... 510k clearance from the Food and Drug Administration,(FDA) to ... United States for 2D,imaging use. EOS 2D|3D technology ... images to be obtained with a low dose of ...
Cached Biology Technology:SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder 2PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday 2PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday 3PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday 4FDA Clears Biospace med's Revolutionary Low Dose Xray Imager 2FDA Clears Biospace med's Revolutionary Low Dose Xray Imager 3FDA Clears Biospace med's Revolutionary Low Dose Xray Imager 4
(Date:11/5/2014)... associate professor of biology in the UTSA College ... the nation selected to receive a two-year $300,00 ... Exploratory Research (EAGER). The funding supports President Obama,s ... to create new technology that will demystify complex ... behaviors in neuroscience are broken into the interactions ...
(Date:11/4/2014)... (Philadelphia, PA) – Temple University School of Medicine ... Explorations winner, an initiative funded by the Bill ... MPH, Professor of Obstetrics, Gynecology and Reproductive Sciences; ... at Temple University School of Medicine will pursue ... titled "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", ...
(Date:11/4/2014)... Lithuania , Nov. 4, 2014   ... technologies, today announced that the latest version of ... in the Ongoing MINEX evaluation organized ... of fingerprint algorithms using the INCITS 378 fingerprint ... mandatory requirement in public tenders in ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Temple University School of Medicine receives Grand Challenges Explorations grant 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3
... TorontoResearchers at the University of Toronto, The Hospital ... University of British Columbia have identified a new treatment ... and an estimated 10% of common colds. The virus, ... most common reason for hospitalization of infants and children ...
... led by St. Jude Children,s Research Hospital scientists has ... childhood eye tumor retinoblastoma. Their work also settles a ... as scrambled as the developmental pathways at work in ... particular type of cell, researchers showed that retinoblastoma is ...
... A recent study suggests that parasites in fish, including ... impacts on fish health than has been assumed, and could ... land use changes cause salmon mortality. It,s not just ... research found, but their numbers that can build up over ...
Cached Biology News:Researchers map pathway of infection for a common, potentially life-threatening respiratory virus 2Childhood eye tumor made up of hybrid cells with jumbled development 2Childhood eye tumor made up of hybrid cells with jumbled development 3Parasite loads an underlying cause of salmon mortality, linked to land use changes 2
... us with target blotted protein on PVDF ... in water), The N-terminal sequence of proteins ... samples purified by HPLC or mono-and bidimensional ... difluoride) membranes using the well known EDMAN ...
Mycoplasma Removal Agent (MRA) has been developed for cell culture, to combat the widespread problems caused by contamination of cell cultures with mycoplasma....
... product contains 5 ml Dynabeads® ... the monoclonal BerEP4 against the ... cell adhesion molecule). Also available ... 2 x 10e7 MNC in ...
albumin from bovine serum (BSA), tetramethylrhodamine conjugate...
Biology Products: